{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:07:56Z","timestamp":1794344876130,"version":"4.9.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24048-x","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:35:59Z","timestamp":1763415359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiopulmonary risk in the COPD patient: the EPOCONSUL audit"],"prefix":"10.1038","volume":"15","author":[{"given":"Myriam","family":"Calle Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Soler-Catalu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Alc\u00e1zar-Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel E.","family":"Fuentes Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Rodr\u00edguez Hermosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"24048_CR1","unstructured":"Chronic obstructive pulmonary disease (COPD). [Internet]. [citado 18 de mayo de 2025]. Disponible en: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic-obstructive-pulmonary-disease-(copd)."},{"key":"24048_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.arbres.2020.08.002","volume":"57","author":"M Miravitlles","year":"2021","unstructured":"Miravitlles, M., Calle, M. & Soler-Catalu\u00f1a, J. J. GesEPOC 2021: one more step towards personalized treatment of COPD. Arch. Bronconeumol. 57, 9\u201310. https:\/\/doi.org\/10.1016\/j.arbres.2020.08.002 (2021).","journal-title":"Arch. Bronconeumol."},{"key":"24048_CR3","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2147\/COPD.S474223","volume":"19","author":"K Meng","year":"2024","unstructured":"Meng, K. et al. Prevalence and impact of chronic obstructive pulmonary disease in ischemic heart disease: A systematic review and Meta-Analysis of 18 million patients. Int. J. Chron. Obstruct Pulmon Dis. 19, 2333\u20132345 (2024). PMID: 39465033; PMCID: PMC11512537.","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"24048_CR4","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.2147\/COPD.S466280","volume":"19","author":"SO Simons","year":"2024","unstructured":"Simons, S. O. Temporal dynamics of cardiovascular risk in patients with chronic obstructive pulmonary disease during stable disease and exacerbations: review of the mechanisms and implications. Int. J. Chron. Obstruct Pulmon Dis. 19, 2259\u20132271 (2024). PMID: 39411574; PMCID: PMC11474009.","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"24048_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejim.2025.01.016","volume":"135","author":"E Pirera","year":"2025","unstructured":"Pirera, E. et al. Risk trajectory of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis. Eur. J. Intern. Med. 135, 74\u201382. https:\/\/doi.org\/10.1016\/j.ejim.2025.01.016 (2025). Epub 2025 Jan 30. PMID:39884921.","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"24048_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","volume":"198","author":"KM Kunisaki","year":"2018","unstructured":"Kunisaki, K. M. et al. SUMMIT Investigators. Exacerbations of chronic obstructive pulmonary disease and cardiac Events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am. J. Respir Crit. Care Med. 198 (1), 51\u201357. https:\/\/doi.org\/10.1164\/rccm.201711-2239OC (2018).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"11","key":"24048_CR7","doi-asserted-by":"publisher","first-page":"e033882","DOI":"10.1161\/JAHA.123.033882","volume":"13","author":"HM Yang","year":"2024","unstructured":"Yang, H. M. et al. COPDGene Investigators. Chronic obstructive pulmonary disease exacerbations increase the risk of subsequent cardiovascular events: A longitudinal analysis of the COPDGene study. J. Am. Heart Assoc. 13 (11), e033882. https:\/\/doi.org\/10.1161\/JAHA.123.033882 (2024).","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"24048_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12931-023-02601-4","volume":"24","author":"KMA Swart","year":"2023","unstructured":"Swart, K. M. A. et al. Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO data network in the Netherlands. Respir Res. 24 (1), 293. https:\/\/doi.org\/10.1186\/s12931-023-02601-4 (2023).","journal-title":"Respir Res."},{"issue":"6","key":"24048_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3390\/jcm14061809","volume":"14","author":"L Anghel","year":"2025","unstructured":"Anghel, L., Ciubar\u0103, A., Patra\u0219, D. & Ciubar\u0103, A. B. Chronic obstructive pulmonary disease and type 2 diabetes mellitus: complex interactions and clinical implications. J. Clin. Med. 14 (6), 1809. https:\/\/doi.org\/10.3390\/jcm14061809 (2025).","journal-title":"J. Clin. Med."},{"issue":"9","key":"24048_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5694\/mja2.50120","volume":"210","author":"P Leong","year":"2019","unstructured":"Leong, P., Macdonald, M. I., Ko, B. S. & Bardin, P. G. Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge. Med. J. Aust. 210 (9), 417\u2013423. https:\/\/doi.org\/10.5694\/mja2.50120 (2019).","journal-title":"Med. J. Aust"},{"issue":"7","key":"24048_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1513\/AnnalsATS.202104-463OC","volume":"19","author":"NM Hawkins","year":"2022","unstructured":"Hawkins, N. M. et al. Control of cardiovascular risk factors in patients with chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 19 (7), 1102\u20131111. https:\/\/doi.org\/10.1513\/AnnalsATS.202104-463OC (2022).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"24048_CR12","doi-asserted-by":"publisher","unstructured":"Balbirsingh, V., Mohammed, A. S., Turner, A. M. & Newnham, M. Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review. Thorax 2022 Jun 30:thoraxjnl-2021-218333. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-218333","DOI":"10.1136\/thoraxjnl-2021-218333"},{"issue":"7","key":"24048_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40265-017-0731-3","volume":"77","author":"M Cazzola","year":"2017","unstructured":"Cazzola, M. et al. Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs 77 (7), 721\u2013732. https:\/\/doi.org\/10.1007\/s40265-017-0731-3 (2017).","journal-title":"Drugs"},{"issue":"5","key":"24048_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.rmed.2014.02.009","volume":"108","author":"L Puente-Maestu","year":"2014","unstructured":"Puente-Maestu, L. et al. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir Med. 108 (5), 737\u2013744. https:\/\/doi.org\/10.1016\/j.rmed.2014.02.009 (2014).","journal-title":"Respir Med."},{"key":"24048_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejim.2024.07.001","volume":"128","author":"A Papi","year":"2024","unstructured":"Papi, A. et al. Long-term inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease, cardiovascular disease, and a recent hospitalised exacerbation: the ICSLIFE pragmatic, randomised controlled study. Eur. J. Intern. Med. 128, 104\u2013111. https:\/\/doi.org\/10.1016\/j.ejim.2024.07.001 (2024).","journal-title":"Eur. J. Intern. Med."},{"key":"24048_CR16","doi-asserted-by":"publisher","unstructured":"Hammadi, A. et al. All-Cause and cardiovascular mortality with single inhaler triple therapy versus double therapies for COPD: A systematic review and Metanalysis. Arch Bronconeumol. Published Online Febr. 21 https:\/\/doi.org\/10.1016\/j.arbres.2025.02.004 (2025).","DOI":"10.1016\/j.arbres.2025.02.004"},{"key":"24048_CR17","doi-asserted-by":"publisher","unstructured":"Calle, M. et al. Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. Int J Chron Obstruct Pulm Dis 2017: 12:417\u2009\u2013\u200926. https:\/\/doi.org\/10.2147\/COPD.S124482","DOI":"10.2147\/COPD.S124482"},{"key":"24048_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.arbres.2023.02.004","volume":"59","author":"M Calle Rubio","year":"2023","unstructured":"Calle Rubio, M. et al. Variations in chronic obstructive pulmonary disease outpatient care in respiratory clinics: results from the 2021 EPOCONSUL audit. Arch. Bronconeumol. 59, 295\u2013304. https:\/\/doi.org\/10.1016\/j.arbres.2023.02.004 (2023).","journal-title":"Arch. Bronconeumol."},{"issue":"3","key":"24048_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/jcm14030707","volume":"14","author":"M Calle Rubio","year":"2025","unstructured":"Calle Rubio, M. et al. Development and validation of a quantitative score for the criteria clinical control in stable COPD proposed in the Spanish COPD guidelines (GesEPOC): results of the EPOCONSUL audit. J. Clin. Med. 14 (3), 707. https:\/\/doi.org\/10.3390\/jcm14030707 (2025).","journal-title":"J. Clin. Med."},{"key":"24048_CR20","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan, M., Mensah George, A., Turco Justine, V., Fuster, V. & Roth Gregory, A. The global burden of cardiovascular diseases and risk. J. Am. Coll. Cardiol. 80, 2361\u20132371 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"24048_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/resp.70103","volume":"30","author":"CK Rhee","year":"2025","unstructured":"Rhee, C. K. et al. Management of COPD with cardiovascular risk in asia: A review by the Asian Pacific society of respirology COPD assembly. Respirology 30 (9), 817\u2013830. https:\/\/doi.org\/10.1111\/resp.70103 (2025).","journal-title":"Respirology"},{"issue":"6","key":"24048_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1042\/CS20210835","volume":"136","author":"K Brassington","year":"2022","unstructured":"Brassington, K., Selemidis, S., Bozinovski, S. & Vlahos, R. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. Clin. Sci. (Lond). 136 (6), 405\u2013423. https:\/\/doi.org\/10.1042\/CS20210835 (2022).","journal-title":"Clin. Sci. (Lond)"},{"issue":"8","key":"24048_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1164\/rccm.202006-2467OC","volume":"205","author":"KM Lodge","year":"2022","unstructured":"Lodge, K. M. et al. Hypoxia increases the potential for Neutrophil-mediated endothelial damage in chronic obstructive pulmonary disease. Am. J. Respir Crit. Care Med. 205 (8), 903\u2013916. https:\/\/doi.org\/10.1164\/rccm.202006-2467OC (2022).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"11","key":"24048_CR24","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1164\/rccm.201604-0690SO","volume":"194","author":"S Roversi","year":"2016","unstructured":"Roversi, S., Fabbri, L. M., Sin, D. D., Hawkins, N. M. & Agust\u00ed, A. Chronic obstructive pulmonary disease and cardiac diseases. An urgent need for integrated care. Am. J. Respir Crit. Care Med. 194 (11), 1319\u20131336. https:\/\/doi.org\/10.1164\/rccm.201604-0690SO (2016).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"3","key":"24048_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5551\/jat.RV22015","volume":"31","author":"M Ishida","year":"2024","unstructured":"Ishida, M., Sakai, C., Kobayashi, Y. & Ishida, T. Cigarette smoking and atherosclerotic cardiovascular disease. J. Atheroscler Thromb. 31 (3), 189\u2013200. https:\/\/doi.org\/10.5551\/jat.RV22015 (2024).","journal-title":"J. Atheroscler Thromb."},{"key":"24048_CR26","doi-asserted-by":"publisher","first-page":"e024350","DOI":"10.1161\/JAHA.121.024350","volume":"11","author":"MT Dransfield","year":"2022","unstructured":"Dransfield, M. T. et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J. Am. Heart Assoc. 11, e024350 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"24048_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/heartjnl-2023-323487","volume":"110","author":"NM Hawkins","year":"2024","unstructured":"Hawkins, N. M. et al. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease. Heart 110, 702\u2013709 (2024).","journal-title":"Heart"},{"issue":"6","key":"24048_CR28","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chest.2024.07.150","volume":"166","author":"O Wallstr\u00f6m","year":"2024","unstructured":"Wallstr\u00f6m, O., Stridsman, C., Lindberg, A., Nyberg, F. & Vanfleteren, L. E. G. W. Exacerbation history and risk of myocardial infarction and pulmonary embolism in COPD. Chest 166 (6), 1347\u20131359. https:\/\/doi.org\/10.1016\/j.chest.2024.07.150 (2024).","journal-title":"Chest"},{"key":"24048_CR29","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1164\/rccm.202307-1122OC","volume":"209","author":"EL Graul","year":"2024","unstructured":"Graul, E. L. et al. Temporal risk of non-fatal cardiovascular events post COPD exacerbation: a population-based study. Am. J. Respir Crit. Care Med. 209, 960\u2013972 (2024).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"1","key":"24048_CR30","doi-asserted-by":"publisher","first-page":"12245","DOI":"10.1038\/s41598-023-39001-z","volume":"13","author":"DP Fuhr","year":"2023","unstructured":"Fuhr, D. P. et al. Examining changes in vascular function, arterial stiffness and systemic inflammation during hospitalization and recovery from an acute exacerbation of chronic obstructive pulmonary disease. Sci. Rep. 13 (1), 12245. https:\/\/doi.org\/10.1038\/s41598-023-39001-z (2023).","journal-title":"Sci. Rep."},{"key":"24048_CR31","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.2147\/COPD.S178149","volume":"13","author":"JJ Soler-Catalu\u00f1a","year":"2018","unstructured":"Soler-Catalu\u00f1a, J. J. et al. Validation of clinical control in COPD as a new tool for optimizing treatment. Int. J. Chron. Obstruct Pulmon Dis. 13, 3719\u20133731. https:\/\/doi.org\/10.2147\/COPD.S178149 (2018).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"issue":"11","key":"24048_CR32","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/resp.13811","volume":"25","author":"M Miravitlles","year":"2020","unstructured":"Miravitlles, M. et al. Predictive value of control of COPD for risk of exacerbations: an international, prospective study. Respirology 25 (11), 1136\u20131143. https:\/\/doi.org\/10.1111\/resp.13811 (2020).","journal-title":"Respirology"},{"key":"24048_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12931-021-01633-y","volume":"22","author":"M Calle Rubio","year":"2021","unstructured":"Calle Rubio, M. et al. COPD clinical control: predictors and long-term follow-up of the CHAIN cohort. Respir Res. 22, 36. https:\/\/doi.org\/10.1186\/s12931-021-01633-y (2021).","journal-title":"Respir Res."},{"key":"24048_CR34","doi-asserted-by":"publisher","unstructured":"Soler-Catalu\u00f1a, J. J. et al. Risk validation of a new quantitative score for clinical control of chronic obstructive pulmonary disease: The RADAR score. Arch Bronconeumol. Jun 16:S0300-2896(25)00216-9. English, Spanish. (2025). https:\/\/doi.org\/10.1016\/j.arbres.2025.06.003. Epub ahead of print. PMID: 40592678.","DOI":"10.1016\/j.arbres.2025.06.003"},{"key":"24048_CR35","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2147\/COPD.S160842","volume":"13","author":"JL L\u00f3pez-Campos","year":"2018","unstructured":"L\u00f3pez-Campos, J. L. et al. Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit. Int. J. Chron. Obstruct Pulmon Dis. 13, 2279\u20132288 (2018).","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"key":"24048_CR36","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.arbres.2023.07.015","volume":"59","author":"M Calle Rubio","year":"2023","unstructured":"Calle Rubio, M. et al. Inhaled maintenance therapy in the Follow-Up of COPD in outpatient respiratory Clinics. Factors related to inhaled corticosteroid Use. EPOCONSUL 2021 audit. Arch. Bronconeumol. 59, 725\u2013735. https:\/\/doi.org\/10.1016\/j.arbres.2023.07.015 (2023).","journal-title":"Arch. Bronconeumol."},{"issue":"18","key":"24048_CR37","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson, D. A. et al. IMPACT Investigators. Once-Daily Single-Inhaler triple versus dual therapy in patients with COPD. N Engl. J. Med. 378 (18), 1671\u20131680. https:\/\/doi.org\/10.1056\/NEJMoa1713901 (2018).","journal-title":"N Engl. J. Med."},{"issue":"10125","key":"24048_CR38","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi, A. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 391 (10125), 1076\u20131084. https:\/\/doi.org\/10.1016\/S0140-6736(18)30206-X (2018).","journal-title":"Lancet"},{"issue":"1","key":"24048_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe, K. F. et al. ETHOS Investigators. Triple inhaled therapy at two glucocorticoid doses in Moderate-to-Very-Severe COPD. N Engl. J. Med. 383 (1), 35\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1916046 (2020).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"24048_CR40","doi-asserted-by":"publisher","first-page":"18973","DOI":"10.1038\/s41598-020-74854-8","volume":"10","author":"J Shin","year":"2020","unstructured":"Shin, J., Yoon, H. Y., Lee, Y. M., Ha, E. & Lee, J. H. Inhaled corticosteroids in COPD and the risk for coronary heart disease: a nationwide cohort study. Sci. Rep. 10 (1), 18973. https:\/\/doi.org\/10.1038\/s41598-020-74854-8 (2020).","journal-title":"Sci. Rep."},{"key":"24048_CR41","doi-asserted-by":"crossref","unstructured":"Ioannides, A. E., Kallis, C., Whittaker, H. R. & Quint, J. K. Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease. Thorax. ;80(2):67\u201375. Thorax. 2025;80(2):67\u201375. (2025).","DOI":"10.1136\/thorax-2024-222113"},{"issue":"1","key":"24048_CR42","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12890-025-03823-6","volume":"25","author":"Y Li","year":"2025","unstructured":"Li, Y., Li, J., Yang, H. & Zhang, Y. Effect of triple therapy on mortality and cardiovascular risk in patients with moderate to severe COPD: a meta-analysis of randomized controlled trials. BMC Pulm Med. 25 (1), 345. https:\/\/doi.org\/10.1186\/s12890-025-03823-6 (2025).","journal-title":"BMC Pulm Med."},{"key":"24048_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf119","author":"CP Gale","year":"2025","unstructured":"Gale, C. P. et al. Identification and management of cardiopulmonary risk in patients with COPD: a multidisciplinary consensus and modified Delphi study. Eur. J. Prev. Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf119 (2025). zwaf119.","journal-title":"Eur. J. Prev. Cardiol."},{"key":"24048_CR44","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.2147\/COPD.S523865","volume":"20","author":"D Shrikrishna","year":"2025","unstructured":"Shrikrishna, D. et al. Chronic obstructive pulmonary disease and the management of cardiopulmonary risk in the UK: A systematic literature review and modified Delphi study. Int. J. Chron. Obstruct Pulmon Dis. 20, 2073\u20132090 (2025). PMID: 40585423; PMCID: PMC12206411.","journal-title":"Int. J. Chron. Obstruct Pulmon Dis."},{"issue":"1","key":"24048_CR45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12931-020-01430-z","volume":"21","author":"U Nilsson","year":"2020","unstructured":"Nilsson, U. et al. Cardiac biomarkers of prognostic importance in chronic obstructive pulmonary disease. Respir Res. 21 (1), 162. https:\/\/doi.org\/10.1186\/s12931-020-01430-z (2020).","journal-title":"Respir Res."},{"issue":"6","key":"24048_CR46","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1164\/rccm.202407-1320ST","volume":"210","author":"LC Myers","year":"2024","unstructured":"Myers, L. C. et al. A research agenda to improve outcomes in patients with chronic obstructive pulmonary disease and cardiovascular disease: an official American thoracic society research statement. Am. J. Respir Crit. Care Med. 210 (6), 715\u2013729. https:\/\/doi.org\/10.1164\/rccm.202407-1320ST (2024). PMID: 39133888; PMCID: PMC11418885.","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"4","key":"24048_CR47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cjco.2025.01.001","volume":"7","author":"M Heffernan","year":"2025","unstructured":"Heffernan, M. & Rutherford, S. The intersection of chronic obstructive pulmonary disease and cardiovascular disease: recent insights in a challenging area. CJC Open. 7 (4), 493\u2013507. https:\/\/doi.org\/10.1016\/j.cjco.2025.01.001 (2025). PMID: 40433143; PMCID: PMC12105754.","journal-title":"CJC Open."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24048-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24048-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T10:04:38Z","timestamp":1763805878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24048-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24048"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24048-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T he authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"JLRH has received speaker fees from Bial, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Zambon and Grifols, and consulting fees from Bial. MM has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi, Zambon and Grifols and research grants from Grifols. JLLC has received honoraria for lecturing, scientific advice, participation in clinical studies or writing for publications for: AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, CSL Behring, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, Megalabs, Novartis and Rovi. JJSC has received speaker fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, FAES, GlaxoSmithKline, Menarini and Novartis, and consulting fees from Bi-al, Chiesi and GSK, and grants from GSK. BAN reports grants and personal fees from GSK, per-sonal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Chiesi, non-financial support from Laboratorios Menarini, grants, personal fees and non-financial support from AstraZeneca, personal fees from Gilead, personal fees and non-financial support from MSD, personal fees from Laboratorios BIAL, personal fees from Zambon, outside the submitted work; in addition, Dr. Alc\u00e1zar-Navarrete has a patent P201730724 issued. MCR has received speaker fees from AstraZeneca, Bial, Chiesi, CSL Behring, GlaxoSmithKline, Menarini, and Grifols, and consulting fees from GlaxoSmithKline and Bial. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Clinical Ethics Committee at the Hospital Cl\u00ednico San Carlos (Madrid, Spain; internal code 20\/722-E).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The need for informed consent was waived because this was a clinical audit, in addition to the non-interventional nature of the study, the anonymization of data and the blind evaluation of the clinical performance. This circumstance was clearly explained in the protocol, and the ethics committees approved this procedure.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}}],"article-number":"40213"}}